Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine

Mayo Clinic Proceedings

Volumn 79, Issue 8, 2004, Pages 1059-1062

  Nasir, Javed M ^a   Durning, Steven J ^a,b   Ferguson, Michael ^b   Barold, Helen S ^b   Haigney, Mark C ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALKALOID; CAFFEINE; CITRUS AURANTIUM EXTRACT; COCA EXTRACT; DEANOL; EPHEDRA EXTRACT; FISETIN; GINGER EXTRACT; GREEN TEA EXTRACT; METHIONINE; OXEDRINE; PHENYLEPHRINE; PLANT EXTRACT; TYROSINE; UNCLASSIFIED DRUG; VITIS VINIFERA EXTRACT; XENADRINE EFX; YERBA MATE EXTRACT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART INFARCTION; HEART PROARRHYTHMIA; HUMAN; ILEX PARAGUARIENSIS; PATIENT MONITORING; QT PROLONGATION; SIDE EFFECT; SOUR ORANGE; STROKE; SUDDEN DEATH; SYMPTOM; SYNCOPE;

EID: 3442876096     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.8.1059     Document Type: Article

References (18)

1. U.S. Food and Drug Administration. Consumer Alert: FDA Plans Regulation Prohibiting Sale of Ephedra-Containing Dietary Supplements and Advises Consumers to Stop Using These Products. December 30, 2003. Available at: www.fda.gov/oc/initiatives/ephedra/december2003/advisory.html. Accessibility verified June 24, 2004.
2. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833-1838.
3. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine [published correction appears in Mayo Clin Proc. 2003;78:1055]. Mayo Clin Proc. 2002;77:12-16.
4. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine [published correction appears in Mayo Clin Proc. 2003;78:1055]. Mayo Clin Proc. 2002;77:12-16.
5. Pellati F, Benvenuti S, Melegari M, Firenzuoli F. Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var. amara by LC. J Pharm Biomed Anal. 2002;29:1113-1119.
6. Niemann RA, Gay ML. Determination of ephedrine alkaloids and synephrine in dietary supplements by column-switching cation exchange high-performance liquid chromatography with scanning-wavelength ultraviolet and fluorescence detection. J Agric Food Chem. 2003;51:5630-5638.
7. Calkins H, Seifert M, Morady F. Clinical presentation and long-term follow-up of athletes with exercise-induced vasodepressor syncope. Am Heart J. 1995;129:1159-1164.
8. Cytodyne LLC. Product Information: Xenadrine EFX. Available at: www.cytodyne.com/products.html?32GEFR. Accessibility verified June 24, 2004.
9. Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother. 2004;38:812-816.
10. Thomas SH, Clark KL, Allen R, Smith SE. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. Br J Clin Pharmacol. 1991;32:705-711.
11. Calapai G, Firenzuoli F, Saitta A, et al. Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report. Fitoterapia. 1999;70:586-592.
12. Robinson RB, Liu QY, Rosen MR. Ionic basis for action potential prolongation by phenylephrine in canine epicardial myocytes. J Cardiovasc Electrophysiol. 2000;11:70-76.
13. Drouin E, Charpentier F, Gauthier C. Alpha1-adrenergic stimulation induces early afterdepolarizations in ferret Purkinje fibers. J Cardiovasc Pharmacol. 1996;27:320-326.
14. Khositseth A, Nemec J, Hejlik J, Shen WK, Ackerman MJ. Effect of phenylephrine provocation on dispersion of repolarization in congenital long QT syndrome. Ann Noninvasive Electrocardiol. 2003;8:208-214.
15. Moss AJ. Long QT syndrome. JAMA. 2003;289:2041-2044.
16. Nemec J, Ackerman MJ, Tester DJ, Hejlik J, Shen WK. Catecholamine- provoked microvoltage T wave alternans in genotyped long QT syndrome. Pacing Clin Electrophysiol. 2003;26:1660-1667.
17. McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA. 2004;291:216-221.
18. Marcus DM, Grollman AP. Ephedra-free is not danger-free [letter]. Science. 2003;301:1669-1671.